, the biotech giant said its existing COVID-19 jab was found to have a six-fold reduction in vaccine-induced antibodies against the B.1.351 variant. Moderna said Wednesday it plans to study three variations of a booster.
Secondly, Moderna said it plans to study a combination of the original vaccine and the variant-specific one in a single jab at 50 micrograms or lower. Lastly, it will study the effects of a third dose of its original vaccine, but at a lower dosage. "Moderna is committed to making as many updates to our vaccine as necessary until the pandemic is under control," Moderna CEO Stephane Bancel said in a statement."We hope to demonstrate that booster doses, if necessary, can be done at lower dose levels, which will allow us to provide many more doses to the global community in late 2021 and 2022 if necessary."